









Markets
/
Stocks
/
nasdaq-eltx
/

Elicio Therapeutics Inc

ELTX

8.320USD

+0.710+9.33%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

143.59MMarket Cap

LossP/E TTM



Elicio Therapeutics Inc

8.320

+0.710+9.33%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Elicio Therapeutics Inc

Currency: USD Updated: 2026-02-06

Key Insights

Elicio Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 146 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 15.50.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Elicio Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

146 / 392

Overall Ranking

291 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Elicio Therapeutics Inc Highlights

StrengthsRisks

Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Company’s clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -2.68, at a low 3-year percentile range.

Held by The Vanguard

Star Investor The Vanguard holds 496.90K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.85.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

15.500

Target Price

+103.68%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Elicio Therapeutics Inc is 6.78, ranking 218 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.78

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.41

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.73

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Elicio Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Elicio Therapeutics Inc is 5.76, ranking 366 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -2.68, which is -682.97% below the recent high of 15.60 and -12.50% above the recent low of -3.01.

Score

Industry at a Glance

Previous score

5.76

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 146/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Elicio Therapeutics Inc is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 15.50, with a high of 18.00 and a low of 13.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

15.500

Target Price

+103.68%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Elicio Therapeutics Inc

ELTX

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Elicio Therapeutics Inc is 6.08, ranking 282 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 9.09 and the support level at 7.46, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.50

Change

0.58

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.019

Neutral

RSI(14)

53.851

Neutral

STOCH(KDJ)(9,3,3)

50.755

Buy

ATR(14)

0.522

Low Volatility

CCI(14)

-3.539

Neutral

Williams %R

28.571

Buy

TRIX(12,20)

-0.045

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

7.998

Buy

MA10

8.057

Buy

MA20

8.009

Buy

MA50

8.138

Buy

MA100

9.040

Sell

MA200

8.689

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Elicio Therapeutics Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 11.00%, representing a quarter-over-quarter decrease of 8.01%. The largest institutional shareholder is The Vanguard, holding a total of 496.90K shares, representing 2.84% of shares outstanding, with 40.90% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

GKCC, LLC

5.42M

Knoll Capital Management, LLC

630.91K

The Vanguard Group, Inc.

Star Investors

473.86K

+4.23%

Actyus Private Equity SGIIC, S.A.

268.56K

-68.64%

Venkatesan (Jay R)

170.22K

-5.71%

Balyasny Asset Management LP

148.08K

Geode Capital Management, L.L.C.

129.69K

+7.33%

Connelly Robert

46.97K

Susquehanna International Group, LLP

120.21K

+606.14%

Marshall Wace LLP

86.53K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Elicio Therapeutics Inc is 3.34, ranking 149 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.